Cross-Module Connection

This module builds directly on the pharmacotherapy foundations established in Modules 3 and 4 (mood stabilizers, atypical antipsychotics, and the bipolar depression treatment algorithm) and the diagnostic framework from Module 2 (differential diagnosis and screening). The pediatric bipolar section connects to the ADHD series (Module 6A: Bipolar as ADHD comorbidity) and the Depression series (Module 6: DMDD). The suicide content cross-references lithium's anti-suicidal properties from Module 3 and the pregnancy section extends the valproate reproductive safety data introduced there. The disparities content connects to the future Schizophrenia series (the diagnostic bias problem linking both diagnoses).

| **In plain language for families: **

Bipolar medications for young people require regular blood tests, not because the medications are dangerous, but because a growing body processes medication differently than an adult body does. A dose that works well at age 12 might become too high or too low by age 14, simply because of how quickly your child is growing. The blood tests let us stay ahead of those changes. Weight and blood sugar checks are especially important for the antipsychotic medications, because these drugs can affect metabolism in ways that matter more the earlier they start.

| **In plain language for families: **

When someone has bipolar disorder and also uses alcohol, marijuana, or other substances, the two problems feed each other in a vicious cycle. The substance use makes the mood swings worse, and the mood swings make the person more likely to use substances. The most important thing families should understand is that these problems need to be treated together, at the same time, by the same team. The old approach of "get sober first, then treat the mood disorder" does not work and actually makes both conditions worse. The goal of mood stabilization is not just to feel better emotionally; when the mood swings are controlled, the drive to self-medicate often decreases on its own.

| **In plain language for families: **

Anxiety and bipolar disorder commonly go together, and when they do, the anxiety makes every part of bipolar disorder harder to manage. The treatment approach follows a clear priority: stabilize the mood first, because trying to treat anxiety without a stable mood foundation tends not to work well and can actually make things worse. Therapy, specifically cognitive-behavioral therapy, is one of the safest and most effective tools available because it works on anxiety without any risk of triggering a mood episode. If anxiety medications are needed, the choice of which one and when to introduce it requires careful consideration by a provider who understands the bipolar context.

| **In plain language for families: **

ADHD and bipolar disorder can genuinely occur together, and when they do, both need treatment. But the order matters enormously. Think of it like building a house: you have to pour the foundation (mood stabilization) before you can frame the walls (ADHD treatment). If you try to treat the ADHD first with stimulant medications before the mood is stable, the stimulant can push the mood in a dangerous direction. Once the mood is solidly stabilized, stimulants can usually be added safely with close monitoring. The key warning sign to watch for is a sudden change in sleep: if your child or family member starts sleeping much less but seems full of energy rather than tired, that is a signal to contact the prescriber immediately, as it may indicate the medication is pushing toward a manic episode.

Section 5: Suicide Risk in Bipolar Disorder

Bipolar disorder carries the highest suicide risk of any psychiatric diagnosis. Every clinician in this module's audience (prescribers, therapists, school psychologists) will encounter bipolar patients with active suicidal ideation. What makes suicide assessment in bipolar disorder different from unipolar depression is that the risk shifts dramatically depending on which mood state the patient is in, and so should the safety plan. This section covers the specific evidence you need: which mood states are most dangerous, why lithium has a unique anti-suicidal effect that should influence your treatment selection, and how to build safety plans that actually account for the phenomenology of each bipolar state.

5.1 The Epidemiological Reality

The rate of suicide among patients with bipolar disorder is approximately 10 to 30 times higher than in the general population, with most estimates clustering around a 15- to 20-fold increase. Up to 20% of primarily untreated patients with bipolar disorder die by suicide. Non-fatal suicidal behaviors are extraordinarily prevalent: a comprehensive meta-analysis by Dong and colleagues (2018, Epidemiology and Psychiatric Sciences) determined a pooled lifetime prevalence of suicide attempts at 33.9% (95% CI 31.3-36.6%) and a one-year prevalence of 15.0% (95% CI 8.2-21.8%).

The lethality of attempts in bipolar disorder is notably higher than in unipolar depression: the ratio of non-fatal attempts to completed suicides is lower, indicating that bipolar patients employ more violent methods and demonstrate higher intent. A 2011 nationwide cohort study * (Nordentoft et al., 2011, Archives of General Psychiatry)* reported the absolute risk of suicide after first hospital contact was highest for bipolar disorder in men (7.8%) and second-highest in women (4.8%, after schizophrenia at 4.9%).

5.2 Mood-State-Specific Risk Factors

Suicidal behavior in bipolar disorder is primarily state-dependent. Understanding which mood states carry the highest risk directly informs clinical vigilance and safety planning.

Bipolar depression: the primary danger zone

Approximately 70% to 80% of all suicide attempts in bipolar disorder occur during depressive episodes. The annual prevalence of suicide attempts during bipolar depression is estimated to be roughly 100 times higher than during euthymic phases. The severe anhedonia, hopelessness, psychomotor retardation (physical and mental slowing, where even basic movements and thought processes feel as if they are moving through thick resistance), and cognitive distortions of bipolar depression create a highly lethal psychological environment. The ISBD Task Force on Suicide * (Schaffer et al., 2015, Bipolar Disorders)* identified depressive polarity of both the first episode and the current episode as among the most statistically significant variables associated with suicide attempts.

Mixed features: the "red zone"

Mixed states, defined by the concurrent presence of depressive symptoms (hopelessness, guilt, suicidal ideation) alongside manic or hypomanic symptoms (psychomotor agitation, racing thoughts, insomnia, impulsivity), create the most dangerous clinical period. An odds ratio of 9.0 for completed suicide in mixed states has been reported * (Brent et al., 1993; cited in Schaffer et al., 2015)* compared to matched bipolar controls without mixed features, though confidence intervals for this estimate were wide given the rarity of the outcome.

The mechanism is clinically straightforward: mixed states combine the severe psychic pain and hopelessness of depression with the energetic drive and impulsivity needed to act on suicidal thoughts. The transition from passive ideation to lethal action can occur with extreme rapidity. This presentation requires immediate, aggressive psychiatric intervention.

Mania and hypomania: lower but not zero risk

Completed suicide during pure euphoric mania or hypomania is rare. However, when suicide does occur during apparent mania, retrospective analysis frequently reveals unrecognized mixed features or a sudden precipitous crash into depression.

5.3 Additional Risk Factors Specific to Bipolar Disorder

Early age of onset. Pediatric or adolescent onset is a robust independent risk factor. Youth with bipolar disorder have a pooled annual suicide attempt rate of approximately 7.5%, over 50 times the general juvenile population rate. Disruption of critical developmental milestones combined with early exposure to mood dysregulation severely compromises long-term resilience.

Prior attempts. A previous suicide attempt yields a Hazard Ratio of 4.10 for completed suicide. Any prior attempt represents a permanent elevation in baseline risk stratification, not a historical footnote.

Bipolar II is not safer. Contemporary meta-analytic data has overturned the assumption that BD-I carries higher suicide risk than BD-II. A meta-analysis of 15 retrospective studies found that the prevalence of attempted suicide was not significantly different between BD-II (32.4%) and BD-I (36.3%), OR 1.21 (95% CI 0.98-1.48, p = .07). Substantial evidence suggests that BD-II patients spend more time depressed, experience more frequent rapid cycling, and use more violent and lethal methods.

Psychiatric comorbidities amplify risk dramatically. Comorbid substance use disorders are the most potent catalysts, and comorbid anxiety independently doubles the odds of a lifetime suicide attempt (Section 3). Comorbid PTSD is particularly dangerous.

Family history of suicide is a potent independent predictor. First-degree relatives of suicide decedents carry substantially elevated risk, with some analyses reporting markedly increased rates among specific family relationships (e.g., offspring of parents who died by suicide), suggesting heritable endophenotypes (measurable biological traits that run in families and sit between the gene level and the clinical symptom level) related to impulsivity and aggression that compound the bipolar illness course.

5.4 The Lithium Anti-Suicidal Effect

Lithium possesses a unique, disease-modifying anti-suicidal property that extends well beyond its general mood-stabilizing effects. If lithium merely prevented mood episodes, other effective mood stabilizers would show identical anti-suicidal properties. They do not.

The meta-analytic evidence

The landmark systematic review and meta-analysis by Cipriani and colleagues (2013, BMJ) analyzed 48 RCTs encompassing 6,674 participants. Lithium was associated with significantly fewer completed suicides compared to placebo, with an odds ratio of 0.13 (95% CI 0.03-0.66). The wide confidence interval reflects the rarity of completed suicide as an outcome, even in high-risk populations; the data confidently establishes that lithium reduces suicide risk, but the precise magnitude ranges considerably, from roughly a one-third reduction to over a ninety percent reduction. Lithium also significantly reduced all-cause mortality (OR 0.38, 95% CI 0.15-0.95). In direct comparison with other mood stabilizers, lithium was significantly superior to carbamazepine specifically for deliberate self-harm (Peto OR 0.14, 95% CI 0.02-0.83).

Baldessarini and Tondo's analyses of maintenance treatment data found that the pooled rate of suicides and attempts was nearly nine times lower during long-term lithium treatment compared to periods without lithium * (Risk Ratio 8.85, 95% CI 4.14-19.1, p < .0001)*, with a calculated NNT of 22.6 (95% CI 21.0-24.6) for maintenance therapy. A 2023 nationwide cohort study of nearly 26,000 hospitalized bipolar patients confirmed these trial findings in real-world data, showing lithium was associated with significantly lower all-cause mortality and suicide compared to valproate, lamotrigine, and carbamazepine.

Proposed mechanisms

The anti-suicidal effect appears to operate through pathways distinct from mood episode prevention:

Reduction of impulsivity and aggression. Lithium exerts a specific modulatory effect on impulsive and aggressive traits, effectively severing the behavioral link between suicidal ideation and the suicide attempt. This mechanism is particularly relevant in mixed states, where impulsivity is at its peak. A patient experiencing suicidal thoughts may not act on them if the impulsive drive to translate thought into action is pharmacologically dampened.

Neuroprotection. Lithium also appears to protect brain cells over time through several molecular mechanisms. One key pathway involves an intracellular signaling enzyme called GSK-3 (glycogen synthase kinase-3), which lithium inhibits. Lithium also modulates both dopaminergic and serotonergic systems and increases levels of BDNF (brain-derived neurotrophic factor), a protein that supports the survival and growth of neurons. Together, these effects may build long-term resilience in the brain circuits that connect the cortex and limbic system, the circuits that govern emotional regulation and that accumulate damage through chronic mood cycling. This neuroprotective action may explain why lithium's anti-suicidal benefit appears to grow stronger with longer treatment duration.

Important caveats

Completed suicide vs. deliberate self-harm. The Cipriani meta-analysis found robust evidence for preventing completed suicides but no clear benefit over placebo for preventing non-fatal deliberate self-harm (OR 0.60, 95% CI 0.27-1.32). This divergence has generated genuine scientific debate. Some researchers have questioned whether the anti-suicidal effect represents a pharmacologically distinct property or is largely a downstream consequence of effective mood episode prevention. The finding that lithium does not reduce non-fatal self-harm complicates the specificity claim. Nonetheless, the consistency of the mortality benefit across multiple study designs, the 2023 nationwide cohort confirmation in nearly 26,000 patients, and the absence of comparable mortality reduction with other effective mood stabilizers (valproate, lamotrigine, carbamazepine) support lithium's unique position in suicide risk management.

The discontinuation rebound. The suicidal risk following lithium cessation is acute, particularly with abrupt discontinuation (less than 14 days). Rates of suicide and attempts spike dramatically upon stopping, with the risk ratio (off vs. on lithium) calculated at 8.85 (p < .0001). Initiating lithium in a patient with severe non-adherence history may paradoxically expose them to rebound risk during future crises. This requires frank discussion with patients about the commitment involved.

Clinical implication for treatment selection

The anti-suicidal evidence should directly inform treatment selection. When managing a bipolar patient with elevated suicide risk, whether from prior attempts, family history, current depressive or mixed features, or comorbid substance use, lithium should be weighted favorably in the treatment algorithm. This does not mean lithium is always the right choice. But the suicide prevention data is a treatment selection factor that should be explicitly considered, not just a background fact.

| **In plain language for families: **

The days and weeks right after someone leaves the hospital are actually the most dangerous period, not the safest. The hospital provided constant structure and monitoring. Coming home means returning to the stresses that may have contributed to the crisis, often while adjusting to new medications. The most important thing a family can do during this transition is ensure the very first outpatient appointment happens within a few days of discharge, not weeks. If the person was started on lithium, making sure they continue taking it exactly as prescribed is critical, because stopping lithium suddenly can trigger a dangerous rebound in suicidal risk. During this transition period, removing firearms from the home, locking up any stockpiled or non-prescribed medications and potentially dangerous household items (while keeping the person's own prescribed psychiatric medications accessible for daily use, with a trusted family member monitoring adherence), and maintaining close daily contact are concrete, evidence-based actions that save lives.

| **In plain language for families: **

If you have bipolar disorder and are pregnant or planning pregnancy, the most important thing to know is that stopping your medication is usually more dangerous than continuing it. The old advice to "stop everything while pregnant" has been replaced by evidence showing that untreated bipolar disorder during pregnancy causes serious harm to both mother and baby. Most medications can be continued with appropriate monitoring and dose adjustments. The one clear exception is valproate (Depakote), which carries unacceptably high risks for the baby's brain development and should be switched to a safer medication before conception whenever possible. After delivery is the highest-risk time; having a plan in place before the baby arrives, including medication that starts the same day as delivery and a strategy for protecting your sleep, can prevent the severe psychiatric emergencies that otherwise affect roughly 1 in 4 to 5 bipolar women.

| **In plain language for families: **

The newer bipolar depression medications (cariprazine and lumateperone) work differently from older options and tend to cause less weight gain and fewer blood sugar problems. Cariprazine works best at a low dose for depression, which is the opposite of what you might expect. Its main side effect is a feeling of restlessness that can be mistaken for anxiety. Lumateperone is one of the best-tolerated options currently available and is notable because it is approved for both Bipolar I and Bipolar II depression. Your prescriber can help determine which medication makes the most sense based on your family member's specific situation, including whether other options have already been tried and how much weight and metabolic effects are a concern.

| **In plain language for families: **

The diagnostic bias section of this module addresses something that affects real patients: research shows that Black patients are systematically more likely to be misdiagnosed with schizophrenia when they actually have bipolar disorder. This matters because the two conditions require very different medications, and getting the wrong diagnosis means getting the wrong treatment, sometimes for years. If you or a family member is Black and has received a schizophrenia diagnosis, but the psychotic symptoms seem to come and go with mood changes rather than being constant, it may be worth asking the treatment team specifically about whether bipolar disorder with psychotic features should be considered.

PsychHQ

Suicide Risk: Epidemiology & Lithium